ANA VAN DER WALL
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology BRADENTON, FL NPI 1265672018
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology FL Merck Sharp & Dohme Corporation All categories
General Payments — all program years on this page
$6,587.29
- Category: General Payments
- Program years: PY2018–2024
- Record count: 352
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,308.30 across 60 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,308.30 | 60 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $181.57 | 7 |
| E.R. Squibb & Sons, L.L.C. | $148.58 | 9 |
| Daiichi Sankyo Inc. | $113.07 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $95.24 | 5 |
| Gilead Sciences, Inc. | $90.27 | 4 |
| PFIZER INC. | $76.23 | 4 |
| ARRAY BIOPHARMA INC | $70.86 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $67.33 | 2 |
| ABBVIE INC. | $59.01 | 2 |
| Astellas Pharma US Inc | $50.46 | 3 |
| Acerta Pharma LLC | $45.52 | 2 |
| Celgene Corporation | $36.85 | 1 |
| SpringWorks Therapeutics, Inc. | $36.46 | 1 |
| Janssen Biotech, Inc. | $32.83 | 2 |
| GENZYME CORPORATION | $30.39 | 2 |
| PharmaEssentia USA Corporation | $29.74 | 1 |
| Dendreon Pharmaceuticals LLC | $23.46 | 1 |
| Stemline Therapeutics Inc. | $23.40 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $19.71 | 1 |
| Myriad Genetic Laboratories, Inc. | $16.93 | 1 |
| Epizyme, Inc. | $16.93 | 1 |
| Genentech USA, Inc. | $15.49 | 1 |
| Sumitomo Pharma America, Inc. | $14.85 | 1 |
| Kite Pharma, Inc. | $13.12 | 1 |
By program year
Records — PY2024 (60)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.